Literature DB >> 15474044

An episodic ataxia type-1 mutation in the S1 segment sensitises the hKv1.1 potassium channel to extracellular Zn2+.

Antonella Cusimano1, Maria Cristina D'Adamo, Mauro Pessia.   

Abstract

Episodic ataxia type-1 (EA1) is a human neurological syndrome characterized by attacks of generalized ataxia and by continuous myokymia that has been associated with point mutations in the voltage-gated potassium channel gene KCNA1. Although important advancement has been made in understanding the molecular pathophysiology of EA1, several disease-causing mechanisms remain poorly understood. F184C is an EA1 mutation that is located within the S1 segment of the human Kv1.1 subunit. Here, we show that the F184C mutation increases approximately 4.5-fold the sensitivity of the channel to extracellular Zn2+. Both Zn2+and Cd2+ markedly alter the activation kinetics of F184C channel. In addition, the mutated channel reacts with several methane thiosulfonate reagents which specifically affected channel function. The results provide structural implications and indicate that sensitisation of hKv1.1 to Zn2+ is likely to contribute to the EA1 symptoms in patients harboring the F184C mutation. Copyright 2004 Federation of European Biochemical Societies

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474044     DOI: 10.1016/j.febslet.2004.09.018

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Kv3 channel assembly, trafficking and activity are regulated by zinc through different binding sites.

Authors:  Yuanzheng Gu; Joshua Barry; Chen Gu
Journal:  J Physiol       Date:  2013-02-18       Impact factor: 5.182

2.  Novel phenotype associated with a mutation in the KCNA1(Kv1.1) gene.

Authors:  Maria C D'Adamo; Constanze Gallenmüller; Ilenio Servettini; Elisabeth Hartl; Stephen J Tucker; Larissa Arning; Saskia Biskup; Alessandro Grottesi; Luca Guglielmi; Paola Imbrici; Pia Bernasconi; Giuseppe Di Giovanni; Fabio Franciolini; Luigi Catacuzzeno; Mauro Pessia; Thomas Klopstock
Journal:  Front Physiol       Date:  2015-01-15       Impact factor: 4.566

3.  Commentary: A channelopathy mutation in the voltage-sensor discloses contributions of a conserved phenylalanine to gating properties of Kv1.1 channels and ataxia.

Authors:  Sonia Hasan; Therese Hunter; Gary Hunter; Mauro Pessia; Maria Cristina D'Adamo
Journal:  Front Cell Neurosci       Date:  2018-06-20       Impact factor: 5.505

Review 4.  New insights into the pathogenesis and therapeutics of episodic ataxia type 1.

Authors:  Maria Cristina D'Adamo; Sonia Hasan; Luca Guglielmi; Ilenio Servettini; Marta Cenciarini; Luigi Catacuzzeno; Fabio Franciolini
Journal:  Front Cell Neurosci       Date:  2015-08-19       Impact factor: 5.505

5.  K(+) channelepsy: progress in the neurobiology of potassium channels and epilepsy.

Authors:  Maria Cristina D'Adamo; Luigi Catacuzzeno; Giuseppe Di Giovanni; Fabio Franciolini; Mauro Pessia
Journal:  Front Cell Neurosci       Date:  2013-09-13       Impact factor: 5.505

6.  A channelopathy mutation in the voltage-sensor discloses contributions of a conserved phenylalanine to gating properties of Kv1.1 channels and ataxia.

Authors:  Sonia Hasan; Cecilia Bove; Gabriella Silvestri; Elide Mantuano; Anna Modoni; Liana Veneziano; Lara Macchioni; Therese Hunter; Gary Hunter; Mauro Pessia; Maria Cristina D'Adamo
Journal:  Sci Rep       Date:  2017-07-04       Impact factor: 4.379

7.  Identification of a New de Novo Mutation Underlying Regressive Episodic Ataxia Type I.

Authors:  Zeynep S Karalok; Alfredo Megaro; Marta Cenciarini; Alev Guven; Sonia M Hasan; Birce D Taskin; Paola Imbrici; Serdar Ceylaner; Mauro Pessia; Maria C D'Adamo
Journal:  Front Neurol       Date:  2018-07-25       Impact factor: 4.003

Review 8.  Kv1.1 Channelopathies: Pathophysiological Mechanisms and Therapeutic Approaches.

Authors:  Maria Cristina D'Adamo; Antonella Liantonio; Jean-Francois Rolland; Mauro Pessia; Paola Imbrici
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.